NYSE$STE
STERIS PLC · Q3 2023 earnings
Q3 2023 earnings · · Investor relations
Briefing
Announced financial results for fiscal 2023 third quarter, featuring a 1% revenue increase and 7% constant currency organic revenue growth.
STERIS plc reported a 1% increase in revenue to $1.22 billion for the third quarter of fiscal 2023, with a 7% constant currency organic revenue growth. Net earnings were $123.8 million, or $1.24 per share, while adjusted EPS reached $2.02. The company updated its fiscal 2023 outlook, anticipating revenue growth of 6% and adjusted EPS in the range of $8.00 to $8.10.
- Revenue increased by 1% as reported, with a 7% constant currency organic revenue growth.
- Reported earnings per share (EPS) stood at $1.24, while adjusted EPS reached $2.02.
- Healthcare segment saw a 1% revenue increase, driven by capital equipment and service growth.
- Applied Sterilization Technologies (AST) revenue increased by 3%, fueled by medical device customer demand.
Headline financials
Revenue & EPS history
STERIS · Revenue · Quarterly
$1.22B
Revenue by segment
STERIS · $1.59B total across 3 segments · Q4 2027
- Healthcare$1.14B—71.5%
- Applied Sterilization Technologies$289M—18.2%
- Life Sciences$163M—10.3%
Forward guidance
STERIS anticipates as reported revenue to grow 6% and adjusted earnings per diluted share to be in the range of $8.00 to $8.10. Free cash flow is expected to be approximately $500 million for fiscal 2023.
Tailwinds
- Revenue is anticipated to grow 6%.
- Currency is now anticipated to negatively impact revenue by approximately $110 million this fiscal year.
- Constant currency organic revenue is now anticipated to grow approximately 7%.
- Adjusted earnings per diluted share are now anticipated to be in the range of $8.00 to $8.10.
- Free cash flow will be approximately $500 million for fiscal 2023.
Headwinds
- As reported revenue is now anticipated to grow 6% compared with prior expectations of 8% growth.
- Currency is now anticipated to negatively impact revenue by approximately $110 million this fiscal year, a reduction from prior expectations of approximately $150 million.
- Constant currency organic revenue is now anticipated to grow approximately 7% compared with prior expectations of 10%.
- Reflecting the lower revenue, adjusted earnings per diluted share are now anticipated to be in the range of $8.00 to $8.10.
- As a result of higher than anticipated working capital requirements, in particular inventory and accounts receivable, STERIS now anticipates free cash flow will be approximately $500 million for fiscal 2023, a decline from prior expectations of $600 million.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2023
+0.5%
Avg return
Earnings day
+1.0%
Avg return
5 days after
+1.3%
Avg return
30 days after
59%
38 / 64 earnings
Positive
+12.9%
Q4 2014
Best reaction
-11.4%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2027 | +0.0% | +7.2% | +2.8% | |
| Q3 2026 | -7.7% | -7.4% | -12.8% | |
| Q2 2026 | +7.0% | +9.7% | +8.3% | |
| Q4 2025 | +8.6% | +10.1% | +6.1% | |
| Q3 2025 | +2.1% | +1.1% | +5.4% | |
| Q2 2025 | -5.2% | -2.5% | -5.1% | |
| Q1 2025 | -1.8% | -0.8% | +0.5% | |
| Q4 2024 | +6.2% | +9.2% | +6.6% | |
| Q3 2024 | -2.5% | -0.4% | +3.4% | |
| Q2 2024 | -5.1% | -8.4% | -7.1% | |
| Q1 2024 | +1.0% | +0.2% | +1.8% | |
| Q4 2023 | +11.2% | +12.7% | +10.6% | |
| Q3 2023 | -11.4% | -9.5% | -18.2% | |
| Q2 2023 | +3.5% | +2.6% | +17.3% | |
| Q1 2023 | -8.8% | -4.7% | -10.0% | |
| Q4 2022 | +1.4% | +1.2% | +2.6% | |
| Q3 2022 | +4.6% | +1.3% | -2.1% | |
| Q2 2022 | -5.5% | -4.8% | -6.4% | |
| Q1 2022 | +0.6% | +1.2% | +0.2% | |
| Q4 2021 | -3.6% | -3.1% | +1.9% | |
| Q3 2021 | -1.9% | -1.7% | -8.1% | |
| Q2 2021 | -0.5% | +2.5% | +8.8% | |
| Q1 2021 | -1.0% | -3.4% | +2.5% | |
| Q4 2020 | +1.2% | +7.0% | +1.8% | |
| Q3 2020 | +6.1% | +10.2% | -5.0% | |
| Q2 2020 | +2.3% | +2.6% | +8.4% | |
| Q1 2020 | +3.0% | +4.1% | +3.0% | |
| Q4 2019 | +1.1% | +3.2% | +10.2% | |
| Q3 2019 | +1.9% | +3.1% | +3.6% | |
| Q2 2019 | +7.0% | +7.4% | +5.4% | |
| Q1 2019 | -0.7% | -1.1% | -1.9% | |
| Q4 2018 | +4.7% | +4.6% | +8.6% | |
| Q3 2018 | -4.7% | -2.8% | +7.8% | |
| Q2 2018 | -6.0% | -6.6% | -3.9% | |
| Q1 2018 | +4.9% | +3.3% | +5.8% | |
| Q4 2017 | +1.4% | -0.4% | +6.4% | |
| Q3 2017 | -6.5% | -5.7% | -3.4% | |
| Q2 2017 | -3.0% | +0.5% | -2.0% | |
| Q1 2017 | -1.6% | -1.9% | -2.0% | |
| Q4 2016 | -0.5% | — | — | |
| Q3 2016 | -1.9% | — | — | |
| Q2 2016 | +6.4% | — | — | |
| Q1 2016 | +0.7% | — | — | |
| Q4 2015 | +2.5% | — | — | |
| Q3 2015 | +1.1% | — | — | |
| Q2 2015 | +3.5% | — | — | |
| Q1 2015 | +0.3% | — | — | |
| Q4 2014 | +12.9% | — | — | |
| Q3 2014 | +0.5% | — | — | |
| Q2 2014 | -3.6% | — | — | |
| Q1 2014 | -3.6% | — | — | |
| Q4 2013 | +8.3% | — | — | |
| Q3 2013 | +1.4% | — | — | |
| Q1 2013 | +1.4% | — | — | |
| Q2 2013 | +1.1% | — | — | |
| Q4 2012 | -0.3% | — | — | |
| Q3 2012 | +0.8% | — | — | |
| Q1 2012 | +0.8% | — | — | |
| Q2 2012 | -4.4% | — | — | |
| Q4 2011 | +0.3% | — | — | |
| Q3 2010 | +0.2% | — | — | |
| Q1 2010 | +0.2% | — | — | |
| Q2 2010 | +0.8% | — | — | |
| Q4 2010 | -0.1% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro